Chemical engineering of a lipid nano-scaffold for the solubility enhancement of an antihyperlipidaemic drug, simvastatin; preparation, optimization, physicochemical characterization and pharmacodynamic study

References

• World Health Organization. Global Health Observatory (GHO) Data [Internet]. Geneva: WHO; 2017. [cited 2017 June 20]. Available from: http://www.who.int/gho/ncd/risk_factors/cholesterol_text/en/
   Google Scholar
• Petyaev IM. Improvement of hepatic bioavailability as a new step for the future of statin. Arch Med Sci. 2015;11:406–410.
   PubMed Web of Science ®Google Scholar
• Lai J, Chen J, Lu Y, et al. Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. in vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. AAPS PharmSciTech. 2009;10:960–966.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112:71–105.
   PubMed Web of Science ®Google Scholar
• Harisa GI, Badran MM. Simvastatin nanolipid carriers decreased hypercholesterolemia induced cholesterol inclusion and phosphatidylserine exposure on human erythrocytes. J Mol Liquids. 2015;208:202–210.
   Web of Science ®Google Scholar
• Kawish SM, Ahmed S, Gull A, et al. Development of nabumetone loaded lipid nano-scaffold for the effective oral delivery; optimization, characterization, drug release and pharmacodynamic study. J Mol Liquids. 2017;231:514–522.
   Web of Science ®Google Scholar
• Müller RH, Mäde K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177.
   PubMed Web of Science ®Google Scholar
• Muller RH, Peterson RD, Hommoss A, et al. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev. 2007;59:522–530.
   PubMed Web of Science ®Google Scholar
• Negi LM, Jaggi M, Talegaonkar S. Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. Int J Pharm. 2014;461:403–410.
   PubMed Web of Science ®Google Scholar
• Moghddam SM, Ahad A, Aqil M, et al. Optimization of nanostructured lipid carriers for topical delivery of nimesulide using Box-Behnken design approach. Artificial Cells Nanomed Biotechnol. 2017;45:617–624.
   PubMed Web of Science ®Google Scholar
• Shete H, Patravale VS. Long chain lipid based tamoxifen NLC. Part I: preformulation, formulation development and physicochemical characterization. Int J Pharm. 2013;454:573–583.
   PubMed Web of Science ®Google Scholar
• Gaba B, Fazil M, Khan S, et al. Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. Bull Fac Pharm Cairo Univ. 2015;53:147–159.
   Google Scholar
• Zhang W, Li X, Ye T, et al. Design, characterization, and in vitro cellular inhibition and uptake ofoptimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology. Int J Pharm. 2013;454:354–366.
   PubMed Web of Science ®Google Scholar
• Alam T, Pandit J, Vohora D, et al. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. Expert Opin Drug Deliv. 2015;12:181–194.
   PubMed Web of Science ®Google Scholar
• Huang ZR, Hua SC, Yang YL, et al. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin. 2008;29:1094–1102.
   PubMed Web of Science ®Google Scholar
• SrivastavaKohli MK, Ali M. Formulation development of novel in situ nanoemulgel (NEG) of ketoprofen for the treatment of periodontitis. Drug Deliv. 2016;23:154–166.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Sarim Imam S, Zafar A, et al. In vitro and preclinical assessment of factorial design based nanoethosomes transgel formulation of an opioid analgesic. Artif Cells Nanomed Biotechnol. 2016;44:1793–1802.
   PubMed Web of Science ®Google Scholar
• Ahmad J, Mir SR, Kohli K, et al. Quality by design approach for self-nanoemulsifying system of paclitaxel. Sci Adv Mater. 2014;6:1778–1791.
   Web of Science ®Google Scholar
• Kumar VV, Chandrasekar D, Ramakrishna S, et al. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm. 2007;335:167–175.
   PubMed Web of Science ®Google Scholar
• Qadri GR, Ahad A, Aqil M, et al. Invasomes of isradipine for enhanced transdermal delivery against hypertension: formulation, characterization and in vivo pharmacodynamic study. Artif Cells Nanomed Biotechnol. 2017;45:139–145.
   PubMed Web of Science ®Google Scholar
• Ali Z, Mishra N, Baldi A. Development and characterization of arteether-loaded nanostructured lipid carriers for the treatment of malaria. Artif Cells Nanomed Biotechnol. 2016;44:545–549.
   PubMed Web of Science ®Google Scholar
• Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm. 2010;401:93–102.
   PubMed Web of Science ®Google Scholar
• Ahmad J, Mir SR, Kohli K, et al. Solid-nanoemulsion preconcentrate for oral delivery of paclitaxel: formulation design, biodistribution, and γ scintigraphy imaging. BioMed Res Int. 2014;2014:984756.
   Google Scholar
• Tsai MJ, Huang YB, Wu PC, et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci. 2011;100:547–557.
   PubMed Web of Science ®Google Scholar
• SahanaSantra B, Basu K, Mukherjee SB. Development of biodegradablepolymerbased tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro evaluation. Int J Nanomedicine. 2010;5:621–630.
   PubMed Web of Science ®Google Scholar
• Zhuanga C, Li Y, Wanga NM, Zhang XN, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 2010;394:179–185.
   PubMedGoogle Scholar
• Rizwanullah M, Amin S, Ahmad J. Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. J Drug Target. 2017;25:58–74.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bu H, Gao Z, et al. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. Int J Pharm. 2010;394:147–153.
   PubMed Web of Science ®Google Scholar
• Alam S, Khan ZI, Mustafa G, et al. Development and evaluation of thymoquinone encapsulated chitosan nanoparticles for nose-to brain targeting: a pharmaco scintigraphic study. Int J Nanomed. 2012;7:5705–5718.
   PubMed Web of Science ®Google Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. Faseb J. 2008;22:659–661.
   PubMed Web of Science ®Google Scholar
• Shin JW, Seol IC, Son CG. Interpretation of animal dose and human equivalent dose for drug development. J Korean Oriental Med. 2010;31:1–7.
   Google Scholar
• Dixit RP, Nagarsenker MS. Formulation and in vivo evaluation of self-nanoemulsifying granules for oral delivery of a combination of ezetimibe and simvastatin. Drug Dev Ind Pharm. 2008;34:1285–1296.
   PubMed Web of Science ®Google Scholar
• Chavhan SS, Petkar KC, Sawant KK. Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies. J Microencapsul. 2013;30:771–779.
   PubMed Web of Science ®Google Scholar
• Magnusson G, Olsson T, Nyberg JA. Toxicity of Pluronic F-68. Toxicol Lett. 1986;30:203–207.
   PubMed Web of Science ®Google Scholar
• Huang J, Si L, Jiang L, et al. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int J Pharm. 2008;356:351–353.
   PubMed Web of Science ®Google Scholar
• Harivardhan Reddy L, Murthy RSR. Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation. AAPS Pharm Sci Technol. 2005;6:E158–E166.
   PubMed Web of Science ®Google Scholar
• Sarmento B, Ferreira D, Veiga F, et al. Characterization of insulin loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr Polym. 2006;66:1–7.
   Web of Science ®Google Scholar
• Aslam M, Aqil M, Ahad A, et al. Application of Box–Behnken design for preparation of glibenclamide loaded lipid based nanoparticles: Optimization, in vitro skin permeation, drug release and in vivo pharmacokinetic study. J Mol Liquids. 2016;219:897–908.
   Web of Science ®Google Scholar